Lv1
60 积分 2025-01-08 加入
Expanding Conjugate Space of RNAi Therapeutics: Ligand at the 3′ End of the Antisense Strand Achieves Uncompromised In Vivo Potency and Efficacy and Reveals Interactions with the Argonaute-2 PAZ Domain
11天前
已完结
Exploring Chemical Modifications for siRNA Therapeutics: A Structural and Functional Outlook
15天前
已完结
RNA interference in the era of nucleic acid therapeutics
15天前
已完结
The chemical structure and phosphorothioate content of hydrophobically modified siRNAs impact extrahepatic distribution and efficacy
15天前
已完结
Challenging the “Undruggable”─Targeting STAT3 but Identifying Potent TrkA-Targeted Inhibitors
18天前
已完结
RNAi-based drug design: considerations and future directions
24天前
已完结
Advancements in the Synthesis of Oxadiazines, Mechanistic insights and Pathways
1个月前
已完结
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs
1个月前
已完结
Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers
1个月前
已完结
Small molecule interleukin 17A/A antagonists and antibodies blocking both IL17A/A & IL17A/F demonstrate equivalent degrees of efficacy in preclinical models of skin and joint inflammation
1个月前
已完结
皖公网安备34019202002308
